In vivo studies demonstrated that MK-8242 delayed tumor growth by a factor of two or more in 10 of 17 solid tumor xenografts containing wild-type TP53, but had no effect on osteosarcoma xenografts with low TP53 expression.377–380 MK-8242 is primarily used for the treatment of acute myeloid leukemia and advanced solid tumors. This evidence concerns the gene TP53 and acute myeloid leukemia.